Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
CHMA Chiasma, Inc. daily Stock Chart
CHMA [NASD]
Chiasma, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-1.28 Insider Own0.10% Shs Outstand31.43M Perf Week-2.46%
Market Cap186.69M Forward P/E- EPS next Y-1.23 Insider Trans-21.80% Shs Float31.43M Perf Month-4.19%
Income-31.30M PEG- EPS next Q-0.34 Inst Own57.80% Short Float0.18% Perf Quarter63.64%
Sales- P/S- EPS this Y-20.90% Inst Trans-0.02% Short Ratio0.41 Perf Half Y61.85%
Book/sh1.40 P/B4.24 EPS next Y3.90% ROA-53.30% Target Price14.25 Perf Year309.66%
Cash/sh1.33 P/C4.48 EPS next 5Y38.70% ROE-69.50% 52W Range1.20 - 7.19 Perf YTD91.00%
Dividend- P/FCF- EPS past 5Y-39.30% ROI- 52W High-17.36% Beta1.48
Dividend %- Quick Ratio2.20 Sales past 5Y- Gross Margin- 52W Low395.00% ATR0.52
Employees18 Current Ratio2.20 Sales Q/Q- Oper. Margin- RSI (14)55.55 Volatility8.83% 10.05%
OptionableNo Debt/Eq0.00 EPS Q/Q-57.80% Profit Margin- Rel Volume0.80 Prev Close5.84
ShortableYes LT Debt/Eq0.00 EarningsMar 19 AMC Payout- Avg Volume142.38K Price5.94
Recom2.00 SMA204.61% SMA5014.92% SMA20069.50% Volume114,508 Change1.71%
Feb-14-19Initiated H.C. Wainwright Buy $11
Jan-17-17Downgrade Barclays Equal Weight → Underweight $5.50 → $2.50
Apr-25-16Downgrade Barclays Overweight → Equal Weight $40 → $5.50
Aug-10-15Initiated Barclays Overweight $40
Apr-03-19 09:25AM  Chiasma Announces Closing of $34.5 Million Offering of Common Stock and Full Exercise of Underwriters Option GlobeNewswire
Mar-29-19 09:25AM  Chiasma Announces Pricing of Underwritten Public Offering of $30.0 Million of Common Stock GlobeNewswire -9.72%
Mar-28-19 05:19PM  5 Stocks Moving In Thursday's After-Hours Session Benzinga
04:01PM  Chiasma Announces Proposed Offering of Common Stock GlobeNewswire
Mar-21-19 04:05PM  Chiasma Announces Three Poster Presentations at ENDO 2019 GlobeNewswire -18.87%
Mar-08-19 04:05PM  Chiasma Reports Fourth Quarter and Year End 2018 Results GlobeNewswire
Mar-04-19 04:05PM  Chiasma to Participate in Three Investor Conferences in March GlobeNewswire +8.70%
Feb-28-19 08:00AM  Chiasma Announces Support for Rare Disease Day 2019 GlobeNewswire
Feb-27-19 12:56PM  Have Insiders Been Buying Chiasma, Inc. (NASDAQ:CHMA) Shares? Simply Wall St.
Jan-03-19 04:05PM  Chiasma Previews Important Upcoming Milestones GlobeNewswire +14.77%
Dec-21-18 09:47AM  Do Directors Own Chiasma, Inc. (NASDAQ:CHMA) Shares? Simply Wall St.
Nov-21-18 08:55AM  Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-08-18 06:03PM  Chiasma: 3Q Earnings Snapshot Associated Press
04:05PM  Chiasma Reports Third Quarter 2018 Results GlobeNewswire
Nov-01-18 08:00AM  Chiasma Supports Acromegaly Awareness Day GlobeNewswire
Oct-17-18 04:05PM  Chiasma Announces Oral Presentation at the 18th Congress of the European Neuroendocrine Association GlobeNewswire
Oct-02-18 09:10AM  The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares Benzinga
Oct-01-18 04:01PM  Chiasma Completes Enrollment of CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly GlobeNewswire
Sep-20-18 01:57PM  One Thing To Consider Before Buying Chiasma Inc (NASDAQ:CHMA) Simply Wall St.
Sep-13-18 04:01PM  Chiasma Announces Poster Presentation at the 9th International Congress of the Growth Hormone Research and IGF Societies GlobeNewswire
Aug-09-18 05:47PM  Chiasma: 2Q Earnings Snapshot Associated Press
04:05PM  Chiasma Reports Second Quarter 2018 Results GlobeNewswire
Jul-25-18 04:05PM  Chiasma Completes Enrollment of MPOWERED(TM) Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly GlobeNewswire
Jun-18-18 04:05PM  Chiasma to Present on New Methodologies in Acromegaly Clinical Trial Design at 12th Acromegaly Consensus Conference GlobeNewswire
Jun-14-18 04:05PM  Chiasma Achieves 50% of Target Patients Randomized in CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly GlobeNewswire
May-14-18 04:05PM  Chiasma Announces FDA Agreement to Redefine Certain Secondary Endpoints in CHIASMA OPTIMAL Phase 3 Clinical Trial GlobeNewswire -6.45%
May-10-18 07:00PM  Chiasma: 1Q Earnings Snapshot Associated Press -6.45%
04:05PM  Chiasma Reports First Quarter 2018 Results GlobeNewswire
Mar-20-18 04:23PM  Chiasma reports 4Q loss Associated Press
04:05PM  Chiasma Reports Fourth Quarter and Year End 2017 Results GlobeNewswire
07:40AM  Blog Exposure - Chiasma to Present Design of Phase-3 Double-Blind Trial of Oral Octreotide Capsules Versus Placebo in Acromegaly Patients at ENDO 2018 ACCESSWIRE
Mar-16-18 08:00AM  Chiasma Announces Poster Presentation at ENDO 2018 on Study Design of Phase 3 Double-Blind Trial Evaluating Oral Octreotide Capsules Versus Placebo in Patients with Acromegaly GlobeNewswire -6.06%
Mar-14-18 09:42AM  Want To Invest In Chiasma Inc (NASDAQ:CHMA)? Heres How It Performed Lately Simply Wall St.
Mar-05-18 08:00AM  Chiasma to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Feb-28-18 08:45AM  Chiasma Honors Patients, Researchers for Rare Disease Day 2018 GlobeNewswire
Jan-08-18 09:00AM  Chiasma Reports on Significant Progress Made During 2017 GlobeNewswire
Nov-09-17 05:03PM  Chiasma reports 3Q loss Associated Press
04:05PM  Chiasma Reports Third Quarter 2017 Results GlobeNewswire
Nov-07-17 09:23AM  Is Chiasma Incs (CHMA) CEO Pay Fair? Simply Wall St.
Nov-01-17 08:50AM  Chiasma Recognizes Acromegaly Awareness Day GlobeNewswire
Sep-27-17 04:05PM  Chiasma Announces First Patient Is Randomized in Phase 3 CHIASMA OPTIMAL Clinical Trial of Octreotide Capsules in Patients with Acromegaly GlobeNewswire
Aug-10-17 09:34PM  Chiasma reports 2Q loss Associated Press
04:02PM  Chiasma Reports Second Quarter 2017 Results GlobeNewswire
04:01PM  Chiasma Reaches Agreement with FDA Under Special Protocol Assessment for a New Phase 3 Clinical Trial of Octreotide Capsules in Acromegaly GlobeNewswire
Jun-19-17 08:18AM  Chiasma Appoints Roni Mamluk, Ph.D. to Board of Directors GlobeNewswire
May-05-17 08:08AM  Chiasma reports 1Q loss Associated Press
08:01AM  Chiasma Reports First Quarter 2017 Results GlobeNewswire
Mar-30-17 04:05PM  Chiasma Announces Poster Presentation at ENDO 2017 on Evaluation of Acromegaly Symptoms from the Newly Developed Acromegaly Treatment Satisfaction Questionnaire GlobeNewswire
Mar-22-17 01:04PM  CHIASMA, INC Financials
Mar-16-17 05:06PM  Chiasma reports 4Q loss Associated Press
04:22PM  CHIASMA, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Chiasma Reports Fourth Quarter and Year End 2016 Results GlobeNewswire
Mar-01-17 08:00AM  Chiasma to Present at the Cowen and Company 37th Annual Health Care Conference GlobeNewswire
Jan-17-17 11:58AM  Chiasma downgraded by Barclays
Jan-09-17 08:17AM  CHIASMA, INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements an
08:00AM  Chiasma Provides Year-End Corporate Update and Preliminary Outlook for 2017 GlobeNewswire
Jan-06-17 09:18AM  Chiasma (CHMA) Shares March Higher, Can It Continue? Zacks
Dec-23-16 11:39AM  Chiasma, Inc. :CHMA-US: Earnings Analysis: Q3, 2016 By the Numbers : December 23, 2016 Capital Cube
11:39AM  Chiasma, Inc. :CHMA-US: Earnings Analysis: Q3, 2016 By the Numbers : December 23, 2016
Dec-16-16 04:17PM  CHIASMA, INC Files SEC form 8-K, Change in Directors or Principal Officers
Nov-09-16 05:25PM  Chiasma reports 3Q loss
04:21PM  CHIASMA, INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal Offi
04:05PM  Chiasma Provides Corporate Update and Reports Third Quarter 2016 Results GlobeNewswire
Nov-04-16 04:37PM  CHIASMA, INC Files SEC form 8-K, Change in Directors or Principal Officers
Nov-01-16 08:00AM  Chiasma Recognizes Acromegaly Awareness Day with New Resources for Patients and Data Presentation for Physicians GlobeNewswire
Sep-30-16 04:30PM  CHIASMA, INC Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and Ex
04:15PM  Chiasma Names Mark J. Fitzpatrick Chief Executive Officer GlobeNewswire
Sep-26-16 08:25AM  Chiasma (CHMA) Shows Strength: Stock Moves 5.9% Higher Zacks
Aug-16-16 09:18AM  CHIASMA, INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Directors or Principal
09:00AM  Chiasma Announces Workforce Reduction GlobeNewswire
Aug-11-16 04:26PM  CHIASMA, INC Files SEC form 10-Q, Quarterly Report
02:35AM  Edited Transcript of CHMA earnings conference call or presentation 10-Aug-16 9:00pm GMT Thomson Reuters StreetEvents
Aug-10-16 06:04PM  Chiasma reports 2Q loss
05:00PM  Chiasma Inc Earnings Call scheduled for 5:00 pm ET today
04:16PM  CHIASMA, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:02PM  Chiasma Provides Corporate Update and Reports Second Quarter 2016 Results GlobeNewswire
07:07AM  Q2 2016 Chiasma Inc Earnings Release - After Market Close
Aug-08-16 10:18AM  FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Chiasma, Inc. (CHMA) and Lead Plaintiff Deadline: August 8, 2016 Accesswire
Aug-05-16 11:59AM  FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Chiasma, Inc. (CHMA) and Lead Plaintiff Deadline August 8, 2016 Accesswire
Aug-04-16 11:25AM  APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Chiasma, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
Aug-03-16 12:28PM  STOCK ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Chiasma, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 8, 2016 Business Wire
11:17AM  UPCOMING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Chiasma, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
10:07AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against Chiasma, Inc. (CHMA) and Lead Plaintiff Deadline August 8, 2016 Accesswire
Jul-29-16 11:18AM  SHAREHOLDER NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Chiasma, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
09:24AM  SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Lawsuit Involving Chiasma, Inc. and a Lead Plaintiff Deadline of August 8, 2016 Business Wire
Jul-27-16 08:00AM  Chiasma to Report Second Quarter 2016 Financial Results on August 10, 2016 GlobeNewswire
Jul-26-16 11:52AM  INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Chiasma, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
10:07AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against Chiasma, Inc. (CHMA) and Lead Plaintiff Deadline - August 8, 2016 Accesswire
Jul-25-16 02:45PM  IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Chiasma, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
12:46PM  DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Chiasma, Inc. Of Upcoming Deadline GlobeNewswire
10:40AM  INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Lawsuit Involving Chiasma, Inc. and a Lead Plaintiff Deadline of August 8, 2016 - CHMA PR Newswire
05:45AM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Chiasma, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
Jul-24-16 09:00AM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Chiasma, Inc. of Class Action Lawsuit and Upcoming Deadline CHMA GlobeNewswire
Jul-21-16 11:42AM  Scott + Scott, LLP Notifies Investors of Chiasma, Inc. (Nasdaq:CHMA) Securities Lawsuit, Encourages Investors With Losses to Contact Firm GlobeNewswire
Jul-20-16 11:15AM  SHAREHOLDER NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Chiasma, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
10:04AM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Chiasma, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 8, 2016 Business Wire
Jul-19-16 05:11PM  INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Chiasma, Inc. And Reminds Investors With Losses To Contact The Firm Accesswire
02:07PM  UPCOMING DEADLINE ALERT CHIASMA, INC. - Brower Piven Reminds Shareholders of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess of $100,000 To Contact The Firm Business Wire
10:21AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Chiasma, Inc. (CHMA) & Lead Plaintiff Deadline August 8, 2016 Accesswire
Jul-15-16 08:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Chiasma, Inc. of Class Action Lawsuit and Upcoming Deadline - CHMA Accesswire
Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mamluk RoniDirectorApr 16Option Exercise0.0910,00090010,000Apr 17 05:19 PM
Mamluk RoniDirectorApr 16Sale5.3110,00053,1000Apr 17 05:19 PM
LUDLAM WILLIAMSee RemarksApr 01Buy5.001,6258,1256,749Apr 02 06:49 PM
Mamluk RoniDirectorMar 05Option Exercise0.095,0004505,000Mar 06 04:34 PM
Mamluk RoniDirectorMar 05Sale5.005,00025,0000Mar 06 04:34 PM
Mamluk RoniDirectorJan 22Option Exercise0.095,0004505,000Jan 23 05:43 PM
Mamluk RoniDirectorJan 22Sale3.675,00018,3700Jan 23 05:43 PM
Fitzpatrick Mark J.President and CEODec 20Buy2.509,61224,0309,612Dec 21 02:03 PM
Minick ScottDirectorSep 20Buy3.0913,00040,17084,220Sep 20 09:21 PM
Minick ScottDirectorSep 19Buy3.068,00024,48071,220Sep 20 09:21 PM
Minick ScottDirectorSep 18Buy3.074,00012,28063,220Sep 20 09:21 PM
Mamluk RoniDirectorJun 18Option Exercise0.092,3892152,389Jun 20 05:19 PM
Mamluk RoniDirectorJun 18Sale1.462,3893,4840Jun 20 05:19 PM
open in yahoo | open in reuters | open in google